Clinical Trial: Standard Second-line Therapy With Toripalimab and Ongericimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07106034) titled 'Standard Second-line Therapy With Toripalimab and Ongericimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial' on July 30.

Brief Summary: The ONTOP study is a prospective, single-arm, open-label phase II clinical trial. A total of 32 patients with advanced MSS/pMMR colorectal cancer who have failed first-line treatment will receive second-line standard treatment combined with Ongericimab and toripalimab. Among them, patients who received irinotecan-containing treatment in the first line will be administered the regimen of Ongericimab + toripalimab + bevacizumab + FOLFOX. Patients who received oxaliplatin-containing treatme...